Abstract: Provided are novel antibodies and antigen-binding fragments thereof that bind interleukin-18 receptor beta (IL-18R?), along with conjugates thereof, nucleic acids encoding the same, compositions comprising the same, and methods of producing and using the same, including in the treatment of various diseases and conditions, such as inflammatory bowel disease, and other immune-mediated diseases, autoimmune diseases, inflammatory diseases, cancers, and infectious diseases.

Abstract: A device for treating roof runoff has a first tube adapted to be axially aligned with, and in fluid communication with, an outlet of a downpipe. The first tube contains a crushed calcium carbonate media. The device has a second tube in fluid communication with the first tube. The first tube and second tube are arranged such that when a flow of roof runoff from the downpipe is at or below a predetermined flow rate, the flow of roof runoff is directed into the first tube to be treated by the crushed calcium carbonate media contained therein, and when the flow of roof runoff is above the predetermined flow rate, excess flow is diverted into the second tube.

Abstract: A device for treating roof runoff has a first tube adapted to be axially aligned with, and in fluid communication with, an outlet of a downpipe. The first tube contains a crushed calcium carbonate media. The device has a second tube in fluid communication with the first tube. The first tube and second tube are arranged such that when a flow of roof runoff from the downpipe is at or below a predetermined flow rate, the flow of roof runoff is directed into the first tube to be treated by the crushed calcium carbonate media contained therein, and when the flow of roof runoff is above the predetermined flow rate, excess flow is diverted into the second tube.

Abstract: A method of performing an immunologic evaluation of a subject, comprising collecting a whole blood sample from the subject, maintaining the sample for at least 6 hours after collection, purifying a population of cells comprising lymphocytes and antigen presenting cells from the maintained sample, optionally by a process incorporating a positive or negative affinity selection step to remove granulocytes, and using the purified cells in a cell-mediated immunoassay (CMI assay).

Abstract: The present invention relates to an accurate, sensitive, and efficient sequential or concurrently sequential method for molecular diagnosis of human papillomavirus (HPV)-based disease, where the method improves the accuracy and reliability of diagnostic and prognostic assessments of HPV-based disease. The method of the invention comprises a primary screen of a sample for HPV nucleic acids, followed by a secondary screen for molecular markers, such as proliferation and cell cycle control group protein markers. The sequential or concurrently sequential method significantly reduces the number of false positive results.

Abstract: A method of performing an immunologic evaluation of a subject, comprising collecting a whole blood sample from the subject, maintaining the sample for at least 6 hours after collection, purifying a population of cells comprising lymphocytes and antigen presenting cells from the maintained sample, optionally by a process incorporating a positive or negative affinity selection step to remove granulocytes, and using the purified cells in a cell-mediated immunoassay (CMI assay).

Abstract: A method of performing an immunologic evaluation of a subject, comprising collecting a whole blood sample from the subject, maintaining the sample for at least 6 hours after collection, purifying a population of cells comprising lymphocytes and antigen presenting cells from the maintained sample, optionally by a process incorporating a positive or negative affinity selection step to remove granulocytes, and using the purified cells in a cell-mediated immunoassay (CMI assay).

Abstract: A method of performing an immunologic evaluation of a subject, comprising collecting a whole blood sample from the subject, maintaining the sample for at least 6 hours after the collection, purifying a population of cells comprising lymphocytes and antigen presenting cells from the maintained sample, optionally by a process incorporating a positive or negative affinity selection step, and using the purified cells in a cell-mediated immunoassay (CMI assay).

Abstract: The present invention relates to an accurate, sensitive, and efficient sequential or concurrently sequential method for molecular diagnosis of human papillomavirus (HPV)-based disease, where the method improves the accuracy and reliability of diagnostic and prognostic assessments of HPV-based disease. The method of the invention comprises a primary screen of a sample for HPV nucleic acids, followed by a secondary screen for molecular markers, such as proliferation and cell cycle control group protein markers. The sequential or concurrently sequential method significantly reduces the number of false positive results.

Abstract: The present invention relates to an accurate, sensitive, and efficient sequential or concurrently sequential method for molecular diagnosis of human papillomavirus (HPV)-based disease, where the method improves the accuracy and reliability of diagnostic and prognostic assessments of HPV-based disease. The method of the invention comprises a primary screen of a sample for HPV nucleic acids, followed by a secondary screen for molecular markers, such as proliferation and cell cycle control group protein markers. The sequential or concurrently sequential method significantly reduces the number of false positive results.

Abstract: The present invention relates to an accurate, sensitive, and efficient sequential or concurrently sequential method for molecular diagnosis of human papillomavirus (HPV)-based disease, where the method improves the accuracy and reliability of diagnostic and prognostic assessments of HPV-based disease. The method of the invention comprises a primary screen of a sample for HPV nucleic acids, followed by a secondary screen for molecular markers, such as proliferation and cell cycle control group protein markers. The sequential or concurrently sequential method significantly reduces the number of false positive results.